<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851953</url>
  </required_header>
  <id_info>
    <org_study_id>AQD 01-15</org_study_id>
    <nct_id>NCT02851953</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety Evaluation of Aqueduct -100 Device</brief_title>
  <official_title>Effectiveness and Safety Evaluation of Aqueduct -100 Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aqueduct Medical Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sintesi Research Srl</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aqueduct Medical Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present clinical investigation is to collect data regarding the safety and
      effectiveness of the Aqueduct 100 device.

      The effectiveness of the Aqueduct 100 will be determined by evaluating the ability to reach
      desired cervical dilation, and the time frame required to reach desired cervical dilation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with dilation of cervix to a pre-determined diameter before the intrauterine procedure using Aqueduct-100 device.</measure>
    <time_frame>Through study completion, approximately 9 months</time_frame>
    <description>The primary outcome of this study is to determine the effectiveness of the Aqueduct-100 device to dilate the uterine cervices to the desired diameter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events: rate, list and severity of AEs and SAEs.</measure>
    <time_frame>Through study completion, approximately 9 months</time_frame>
    <description>In vivo safety evaluation of using Aqueduct-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time frame required to reach desired cervical dilation from start time (insertion of device) to completion of dilation (removal of catheter)</measure>
    <time_frame>Through study completion, approximately 9 months</time_frame>
    <description>Duration of the dilation procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of physicians' satisfaction with the device, through the use of a questionnaire.</measure>
    <time_frame>Through study completion, approximately 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Cervix Uteri Dilation</condition>
  <arm_group>
    <arm_group_label>Aqueduct 100 dilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uterine cervix dilation through Aqueduct-100 device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aqueduct-100</intervention_name>
    <arm_group_label>Aqueduct 100 dilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects, females, 18 years of age or older.

          2. Subjects undergoing any process that requires dilation (intrauterine procedures).

          3. Subjects understanding the nature of the study and willing to sign informed consent
             form.

        Exclusion Criteria:

          1. Subjects younger than 18 years of age.

          2. Subject with the following infectious diseases: HIV, HBV, HCV, Syphilis.

          3. Subject has been treated with any cervix dilating agent within 2 months before the
             screening.

          4. Known contraindications or hypersensitivity to the components of the investigational
             product.

          5. The patient has a condition or a concurrent severe and/or uncontrolled medical disease
             which could compromise participation, compliance with, and/or completion with study
             procedures.

          6. Subjects undergoing abortion &lt;7 and &gt;9 weeks of pregnancy.

          7. Subjects unwilling to sign the informed consent form.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierluigi Venturini, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simone Ferrero, Professor</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO IST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irccs Azienda Ospedaliera Universitaria San Martino Ist</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mazza E, Nava A, Bauer M, Winter R, Bajka M, Holzapfel GA. Mechanical properties of the human uterine cervix: an in vivo study. Med Image Anal. 2006 Apr;10(2):125-36. Epub 2005 Sep 6.</citation>
    <PMID>16143559</PMID>
  </reference>
  <reference>
    <citation>Buhimschi, C.; Buhimschi, I.; Malinow, A.; Saade, G.; Garfield, R.; Weiner, C., The Forces of Labour. Fetal and Maternal Medicine Review 2003, 14 (4), 273-307.</citation>
  </reference>
  <reference>
    <citation>Myers KM, Paskaleva AP, House M, Socrate S. Mechanical and biochemical properties of human cervical tissue. Acta Biomater. 2008 Jan;4(1):104-16. Epub 2007 Sep 27.</citation>
    <PMID>17904431</PMID>
  </reference>
  <reference>
    <citation>Kenyon NJ, Stevens JC, Stewart P, Black MM, Clifford A. A critical investigation of the measurement of the force required to dilate the human uterine cervix. Clin Phys Physiol Meas. 1988 May;9(2):155-61.</citation>
    <PMID>3391017</PMID>
  </reference>
  <reference>
    <citation>S. Febvay, S. Socrate and M.D. House. Biomechanical modeling of cervical tissue. A quantitative investigation of cervical funneling. Proceedings of the ASME 2003 International Mechanical Engineering Congress and Exposition, Washington, D.C., November 2003.</citation>
  </reference>
  <reference>
    <citation>Arsenijevic S, Vukcevic-Globarevic G, Volarevic V, Macuzic I, Todorovic P, Tanaskovic I, Mijailovic M, Raicevic S, Jeremic B. Continuous controllable balloon dilation: a novel approach for cervix dilation. Trials. 2012 Oct 22;13:196. doi: 10.1186/1745-6215-13-196.</citation>
    <PMID>23088906</PMID>
  </reference>
  <reference>
    <citation>Nicolaides KH, Welch CC, MacPherson MB, Johnson IR, Filshie GM. Lamicel: a new technique for cervical dilatation before first trimester abortion. Br J Obstet Gynaecol. 1983 May;90(5):475-9.</citation>
    <PMID>6849849</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervix, cervical dilation, balloon catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

